21 CFR 211.113
Procedures for sterile drug products
- Inspections citing it: 1,235
- Of those classified, ended OAI: 45%
- Last cited: FY2026
Inspections Citing It by Fiscal Year
Sites in and outside the US, FY2017 to Oct 20, 2026.
Paragraphs Cited
As FDA posts them, all years.
- 211.113(b)
- 907 · Procedures for sterile drug products
- 211.113(a)
- 328 · Procedures for non-sterile drug products
Regulation Text
eCFR did not answer; open it on eCFRRecently Cited Sites
Newest inspections citing this section; each opens the site- Baxter Healthcare CorporationUnited States · Sep 23, 2026
- Steril-Gene Life Sciences Private LtdIndia · Aug 12, 2026
- Meridian Medical Technologies, LLC a Subsidiary of Kindeva Drug Delivery, L.P.United States · Jun 30, 2026
- OneSource Specialty Pharma LimitedIndia · Jun 30, 2026
- S.s.s. Company (international)United States · Jun 26, 2026
- Owen Biosciences Inc.United States · May 15, 2026
- Advagen Holdings, Inc.United States · May 13, 2026
- SnugZ USA, Inc.United States · May 1, 2026
Counts are inspections with posted citations that cite any paragraph of the section, once per inspection, from FDA's Data Dashboard. OAI share is over inspections FDA finally classified. Text from eCFR, the official online CFR. FDA Data Dashboard and eCFR